A non-catalytic role of choline kinase alpha is important in promoting cancer cell survival

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Falcon, S C ^a   Hudson, C S ^a   Huang, Y ^a   Mortimore, M ^a   Golec, J M ^a   Charlton, P A ^a   Weber, P ^a   Sundaram, H ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Apoptosis; Choline kinase alpha; Inhibitor; Scaffolding; SiRNA

Indexed keywords

CHOLINE KINASE; CHOLINE KINASE ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CHKA PROTEIN, HUMAN; PHOSPHORYLCHOLINE;

APOPTOSIS; ARTICLE; CANCER CELL; CATALYSIS; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; HELA CELL; IC 50; PHENOTYPE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; HELA CELL LINE; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CELL SURVIVAL; CHOLINE KINASE; HELA CELLS; HUMANS; NEOPLASMS; PHOSPHORYLCHOLINE; RNA, SMALL INTERFERING;

EID: 84880565624     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.2     Document Type: Article

References (22)

1. Kennedy EP. Metabolism of lipids. Ann Rev Biochem 1957; 26: 119-148.
2. Cuadrado A, Carnero A, Dolfi F, Kimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993; 8: 2959-2968.
3. Gibellini F, Smith TK. The Kennedy pathway - De novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life 2010; 63: 414-428.
4. Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J et al. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signalling. Oncogene 2009; 29: 139-149.
5. Mori N, Glunde C, Takagi T, Raman V, Bhujwalla Z. Choline kinase down regulation increases the effect of 5-Fluorouracil in breast cancer cell. Cancer Res 2007; 67: 11284-11290.
6. Banez-Coronel M, Ramirez de Molina A, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, Garcia-Cabezas MA et al. Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 2008; 8: 709-719.
7. Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal JC. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 2005; 65: 5647-5653.
8. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res 1999; 90: 419-424.
9. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez JJ, Bonilla F et al. Overexpression of choline kinase is a frequent feature in human tumor derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Comms 2002; 296: 580-583.
10. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M et al. Activation of phosphocholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res 2005; 65: 9369-9376.
11. Gabellieri C, Beloueche-babari M, Jamin Y, Payne GS, Leach MO, Eykyn TR. Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR. NMR Biomed 2009; 22: 456-461.
12. Hernando E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramirez de Molina V, Cejas P et al. A critical role for choline kinase-α in the aggressiveness of bladder carcinomas. Oncogene 2009; 28: 2425-2435.
13. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P et al. Expression of choline kinase alpha to predict outcome in patients with early stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007; 8: 889-897.
14. Glunde K, Jacobs MA, Bhujwalla Z. Choline metabolism in cancer: Implications for diagnosis and therapy. Expert Rev Mol Diagn 2006; 6: 821-829.
15. Rauch J, Volinsky N, Romano D, Kolch W. The secret life of kinases: functions beyond catalysis. Cell Commun Signal 2011; 9: 23.
16. Miyake T, Parsons SJ. Functional interactions between choline kinase-α, epidermal growth factor receptor and c-Src in breast cancer cell proliferation. Oncogene 2012; 31: 1431-1441.
17. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA et al. Choline kinase inhibitors as a novel approach for anti-proliferative drug design. Oncogene 1997; 15: 2289-2301.
18. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Medias D et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Research 2004; 64: 6732-6739.
19. Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, Telang S et al. A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signalling. Oncogene 2011; 30: 3370-3380.
20. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a specific and highly selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004; 23: 8247-8259.
21. Rodriguez-Gonzalez A, Ramirez de Molina A, Banez-Coronel M, Megias D, Lacal JC. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncology 2005; 26: 999-1008.
22. Goldman PR, Northrop DB. Purification and spectrophotometric assay of neomycin phosphotransferase II1. Biochem Biophys Res Commun 1976; 69: 230-236.